Novel Therapies for the Treatment of Drug-Induced Liver Injury: A Systematic Review
Новые методы лечения лекарственно-индуцированного поражения печени: систематический обзор
2022-02-02
SCID: 54.1/ax8ysr9y
Discuss with AI
alanine aminotransferase normalizationdrug-induced liver injurymagnesium isoglycyrrhizinatenovel therapiessystematic review
Figures from the paper
Abstract (AI)
PubMed), CENTRAL, Science Citation Index Expanded, clinical trials registries and databases of DILI and hepatotoxicity up to 2021 for novel therapies for the management of adult patients with DILI based on the combination of three main search terms: 1) treatment, 2) novel, and 3) drug-induced liver injury. The mechanism of action of novel therapies, the potential of their benefit in clinical settings, and adverse drug reactions related to novel therapies were extracted. Cochrane Risk of bias tool and Grading of Recommendations Assessment, Development and Evaluation (GRADE) assessment approach was involved in the assessment of the certainty of the evidence for primary outcomes of included studies. One thousand three hundred seventy-two articles were identified. Twenty-eight articles were included in the final analysis. Eight randomized controlled trials (RCTs) were detected and for six the available data were sufficient for analysis. In abstract form only we found six studies which were also anaylzed. Investigated agents included: bicyclol, calmangafodipir, cytisin amidophospate, fomepizole, livina-polyherbal preparation, magnesium isoglycyrrhizinate (MgIG), picroliv, plasma exchange, radix Paeoniae Rubra, and S-adenosylmethionine. The primary outcomes of included trials mainly included laboratory markers improvement. Based on the moderate-certainty evidence, more patients treated with MgIG experienced alanine aminotransferase (ALT) normalization compared to placebo. Low-certainty evidence suggests that bicyclol treatment leads to a reduction of ALT levels compared to phosphatidylcholine. For the remaining eight interventions, the certainty of the evidence for primary outcomes was assessed as very low and we are very uncertain in any estimate of effect. More effort should be involved to investigate the novel treatment of DILI. Well-designed RCTs with appropriate sample sizes, comparable groups and precise, not only surrogate outcomes are urgently welcome.
Key Findings
1
Eight randomized controlled trials were identified, but sufficient data for analysis were available from only six; six additional studies were available only as abstracts.
2
Low-certainty evidence suggested bicyclol reduced alanine aminotransferase levels compared with phosphatidylcholine; evidence for eight other interventions was very uncertain.
3
Moderate-certainty evidence showed that magnesium isoglycyrrhizinate increased alanine aminotransferase normalization compared with placebo.
4
Most trials assessed laboratory-marker improvement rather than clinically meaningful outcomes, highlighting the need for adequately powered, well-designed RCTs with precise non-surrogate endpoints.
5
The evaluated interventions included bicyclol, calmangafodipir, fomepizole, magnesium isoglycyrrhizinate, plasma exchange, S-adenosylmethionine, and other agents.
6
This systematic review identified 1,372 records and included 28 studies evaluating novel therapies for adult drug-induced liver injury (DILI).
Research Object
novel therapies for adult patients with drug-induced liver injury (DILI)
Research Subject
their clinical efficacy, mechanisms of action, safety, and effects on liver-injury laboratory markers
Publication Details
Publication Date
2022-02-02
Journal
Publisher
ISSN
Cited by
52
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest